Search

Your search keyword '"Amphotericin B pharmacology"' showing total 4,517 results

Search Constraints

Start Over You searched for: Descriptor "Amphotericin B pharmacology" Remove constraint Descriptor: "Amphotericin B pharmacology"
4,517 results on '"Amphotericin B pharmacology"'

Search Results

201. Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo .

202. Design of double functionalized carbon nanotube for amphotericin B and genetic material delivery.

203. Effect of Antibiotic Amphotericin B Combinations with Selected 1,3,4-Thiadiazole Derivatives on RPTECs in an In Vitro Model.

204. Meyerozyma guilliermondii species complex: review of current epidemiology, antifungal resistance, and mechanisms.

205. Nicotinamide potentiates amphotericin B activity against Candida albicans .

206. In-situ degradation of Amphotericin B in a microbial electrochemical cell containing wastewater.

207. Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India.

208. The molecular and genetic basis of antifungal resistance in the emerging fungal pathogen Candida auris.

209. In vitro ability of Fusarium keratoplasticum to form biofilms in venous catheter.

210. Induction of amphotericin B resistance in susceptible Candida auris by extracellular vesicles.

211. Amphotericin B-Loaded Plant-Inspired Polyphenol Nanoparticles Enhance Its Antifungal Activity and Biocompatibility.

212. Liposomal Amphotericin B Formulation Displaying Lipid-Modified Chitin-Binding Domains with Enhanced Antifungal Activity.

213. Development, Characterization, and In Vitro Biological Performance of Amphotericin B and Terbinafine Microemulsions Against Leishmania major.

214. High-throughput assay for effect screening of amphotericin B and bioactive components on filamentous Candida albicans.

215. Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species.

216. Leishmania amazonensis from distinct clinical forms/hosts has polymorphisms in Lipophosphoglycans, displays variations in immunomodulatory properties and, susceptibility to antileishmanial drugs.

217. Amphotericin B: A drug of choice for Visceral Leishmaniasis.

218. Metallacarborane Derivatives as Innovative Anti- Candida albicans Agents.

219. Indications that the Antimycotic Drug Amphotericin B Enhances the Impact of Platelets on Aspergillus.

220. Evaluation of the Efficacy of Amphotericin B and Terbinafine Microemulsions and Their Combination on Cutaneous Leishmaniasis and Comparison with the Conventional Drug Form in BALB/c Mice.

221. Molecular Mechanisms of Antifungal Resistance in Mucormycosis.

222. Amphotericin B resistance in Leishmania mexicana: Alterations to sterol metabolism and oxidative stress response.

223. Hijacking the intrinsic vitamin B 12 pathway for the oral delivery of nanoparticles, resulting in enhanced in vivo anti-leishmanial activity.

224. EUCAST-Obtained Olorofim MICs against Aspergillus and Scedosporium Species and Lomentospora prolificans Showed High Agreements between Visual Inspection and Spectrophotometric Readings.

225. Mechanism of Antifungal Action of Monoterpene Isoespintanol against Clinical Isolates of Candida tropicalis .

226. In vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and/or amphotericin B.

227. High MICs for antifungal agents in yeasts from an anthropized lagoon in South America.

228. Investigation of the Defective Growth Pattern and Multidrug Resistance in a Clinical Isolate of Candida glabrata Using Whole-Genome Sequencing and Computational Biology Applications.

229. Shockwaves Increase In Vitro Resilience of Rhizopus oryzae Biofilm under Amphotericin B Treatment.

230. Fungal Keratitis Treatment Using Drug-Loaded Hyaluronic Acid Microgels.

231. Malassezia species: the need to establish epidemiological cutoff values.

232. Exploring direct and indirect targets of current antileishmanial drugs using a novel thermal proteomics profiling approach.

233. Cholesterol improves stability of amphotericin B nanoemulsion: promising use in the treatment of cutaneous leishmaniasis.

234. Amphiphilic hyperbranched polyglycerol nanoarchitectures for Amphotericin B delivery in Candida infections.

235. Triple-combination therapy for cutaneous leishmaniasis using detergent-free, hyaluronate-coated elastic nanovesicles.

236. Analysis of the effects of different nitrogen sources and calcium on the production of amphotericin by Streptomyces nodosus based on comparative transcriptome.

237. In Vitro Interactions of Antifungal Agents and Everolimus Against Aspergillus Species.

238. The in-vitro study of novel phospholipid micelles loaded with amphotericin B on plasmodium falciparum protozoan.

239. Antifungal efficacy of pure boron on yeast and mold isolates causing superficial mycosis.

240. Evaluation of the effect of conventional and natural antifungals on motility and kinetics of cooled stallion semen.

241. Multicenter Study of Susceptibility of Aspergillus Species Isolated from Iranian University Hospitals to Seven Antifungal Agents.

242. Comparative Transcriptomics Reveal Possible Mechanisms of Amphotericin B Resistance in Candida auris.

243. Antifungal effect of triclosan on Aspergillus fumigatus: quorum quenching role as a single agent and synergy with liposomal amphotericin-B.

244. Independent Evaluation of Cell Culture Systems for Hepatitis E Virus.

245. In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris.

246. Antifungal activity of [K 3 ]temporin-SHa against medically relevant yeasts and moulds.

247. Prevalence and susceptibility profiles of oral yeast species isolated from a healthy adult Thai cohort.

248. Aspergillus tubingensis Endocarditis: A Case Report and Review of the Literature.

249. Inhibition of azole-resistant Aspergillus fumigatus biofilm at various formation stages by antifungal drugs, including olorofim.

250. Species Distribution and Antifungal Susceptibilities of Aspergillus Section Fumigati Isolates in Clinical Samples from the United States.

Catalog

Books, media, physical & digital resources